The NeuroMex study was a collaboration between the Ó³»´«Ã½, Harvard T.H. Chan School of Public Health and the Ramón de la Fuente Muñiz National Institute of Psychiatry (INPRFM) and led by Drs. Karestan Koenen and Beatriz Camarena Medellin. The NeuroMex study aimed to expand knowledge of the genetic and environmental risk factors for neuropsychiatric disorders in Mexico through large-scale sample collection and analysis, so that future advances in science and therapeutics could account for and be applicable to Mexican populations. Additionally, the study sought to further the field's understanding of the genetics of Mexican populations while also enhancing genetic research capacity in Mexico through the training of scientists and supporting the development of locally led research programs.
The NeuroMex team — comprising researchers, clinicians, project managers, and others in the United States and multiple institutions in Mexico — collected and genetically analyzed blood and saliva samples from 9,318 participants [4,693 with a diagnosis of a psychotic disorder and 4,625 without (controls)] between 2018 and 2024. Participants were from the following regions in Mexico:
Participant recruitment sites for NeuroMex (Sitios de reclutamiento en el estudio de NeuroMex)
To learn more about the NeuroMex study, the published protocol is available .
Upcoming Research Project:
The NeuroMex team is looking forward to starting a new research study that will look at the genetics of eating disorders. Stay tuned for more information.